touchSYMPOSIUM HIGHLIGHTS

A clear case of metabolic syndrome – or could it be lipodystrophy?

Watch Time: 85 mins

Faculty Presenters: Prof. David Araújo-Vilar, Prof. Martin Wabitsch, Prof. Barış Akıncı

This content is available for free to registered healthcare professionals in the EU only.

to access this content

This activity has been sponsored by Amryt Pharmaceuticals DAC. Amryt Pharmaceuticals DAC organised the symposium at the e-ECE 2020, provided financial support, and has had input into the selection of the faculty and/or the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchENDOCRINOLOGY

This content is for healthcare professionals only.

Please confirm that you are a healthcare professional.

Decline

This activity has been sponsored by Amryt Pharmaceuticals DAC. Amryt Pharmaceuticals DAC organised the symposium at the e-ECE 2020, provided financial support, and has had input into the selection of the faculty and/or the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchENDOCRINOLOGY

General Endocrinology View Time: 85 mins

touchSYMPOSIUM HIGHLIGHTS A clear case of metabolic syndrome – or could it be lipodystrophy?

Watch this two-part activity to see leading endocrinologists discuss the diagnoses, disease burden and effective management of lipodystrophy. This activity provides key highlights from a symposium sponsored by Amryt Pharmaceuticals DAC, held at the e-ECE 2020: the 22nd European Congress of Endocrinology in September 2020.

Part 1: Watch the symposium presentations from Prof. Martin Wabitsch and Prof. Barış Akıncı Watch Now
Part 2: Gain insight from interviews with three leading lipodystrophy experts Select An Interview

  • Part 1: Symposium Presentations
Next Chapter
A clear case of metabolic syndrome...or is it?
Living with lipodystrophy and the urgency to treat
Back in the clinic - an interactive case presentation with Q&A
Q&A session
 
Leave Feedback
Overview

A clear case of metablic syndrome - or could it be lipodystrophy?

Symposium presentations by three leading experts in lipodystrophy.

About Faculty

Prof. Martin Wabitsch
University of Ulm, Germany

Martin Wabitsch MD, PhD is Professor of Paediatrics at the University of Ulm, Germany and is head of the Division of Paediatric Endocrinology and Diabetes and the Endocrine Research lab at the Department of Paediatrics and Adolescents Medicine in Ulm’s University Hospital.

Prof. Barış Akıncı
Brehm Center for Diabetes, University of Michigan, Ann Arbor, MI, USA, and Division of Endocrinology and Metablism, Dokuz Eylul University, Ismir, Turkey

Prof. Barış Akıncı is a key global opinion leader in the diagnosises & management of lipodystrohy. He is a clinical professor at Dokuz Eylul University, Turkey, and since 2018, he has been working with Dr. Elif Oral at the University of Michigan in the US.

Disclosures

Prof. Wabitsch: Consultant/speaker fees from: Amryt Pharmaceuticals DAC, InfectoPharm, Novo Nordisk, Rhythm Pharmaceuticals, Merck Serono and Abbott.

Prof. Barış Akıncı: Consultant fees from: Amryt Pharmaceuticals DAC.

Downloads

View and download resources from this activity to support your learning or share with colleagues.

  • Part 2: Expert Interviews
Leave Feedback
Prof. David Araújo-Vilar
Watch Time: 06:18
Professor of Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Spain

Prof. David Araújo-Vilar describes the main challenges patients face on their journey to a diagnosis of lipodystrophy, the role of speicalist centres in diagnosis and how diagnosis can be improved.

 
Leave Feedback
Interview Questions

In this interview we asked Prof. David Araújo-Vilar the following questions:

  • What is lipodystrophy? What are the main signs and symptoms?
  • What are the main challenges in the patient journey to a diagnosis of lipodystrophy?
  • what signs and symptoms could lead to a suspicion or lipodystrophy?
  • How is a definitive diagnosis made?
  • What role do specialist centres have in the diagnosis and management of lipodystrophy?
  • How could the patient journey to diagnosis and effective management be improved?
About Prof. David Araújo-Vilar

Professor of Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Spain

Professor David Araújo-Vilar is a Tenure Associate Professor of Medicine, Senior Consultant in Endocrinology and Nutrition, Coordinator of the Area of Medicine and a full-time Professor of Medicine since 1998 at the School of Medicine at the University of Santiago de Compostela, Prof. Araújo-Vilar has published more than 60 papers in peer-review journals and is also the current President of the European Consortium of Lipodystrophies (ECLip).

Disclosures:

Consultant fees from: Amryt Pharmaceuticals DAC

Prof. Martin Wabitsch
Watch Time: 06:40
Professor of Paediatrics, University of Ulm, Germany

Prof. Martin Wabitsch provides an overview of the main signs and symptoms of lipodystrophy and which ones are the most difficult to manage, in addition to describing the objectives of treatment and the triggers for re-evaluating management.

 
Leave Feedback
Interview Questions

In this interview we asked Prof. Martin Wabitsch the following questions:

  • What are the main signs and symptoms of lipodystrophy?
  • Which complications are most difficult to manage?
  • What disease process is causing these issues?
  • For you, what are the patient factors that trigger a revaluation of lipodystrophy management?
  • What are your objectives for treatment?
  • How can management of lipodystrophy be improved?
About Prof. Martin Wabitsch

Professor of Paediatrics, Head of the Division of Endocrinology and Paediatric Endocrinology of Diabetes, Children’s Hospital of the University of Ulm, Germany

Martin Wabitsch MD, PhD is Professor of Paediatrics at the University of Ulm, Germany and is the Head of the Division of Paediatric Endocrinology and Diabetes at the Department of Paediatrics and Adolescents Medicine in Ulm’s University Hospital. Prof. Wabitsch is also the chair of the Ulm University Center for Rare Endoncrine Diseases. He has been the President of the German Society for Paediatric Endocrinology and Diabetes from 2008-2012 and the President of the German Obesity Society from 2012 – 2015.

Disclosures:

Consultant/speaker fees from: Amryt Pharmaceuticals DAC, InfectoPharm, Novo Nordisk, Rhythm Pharmaceuticals, Merck Serono, and Abbott.

Prof. Barış Akıncı
Watch Time: 06:14
Brehm Center for Diabetes, University of Michigan, Ann Arbor, MI, USA and Division of Endocrinology and Metablism, Dokuz Eylul University, Turkey

Prof. Barış Akıncı outlines the burden of lipodystrophy, why it is important to get symptoms under control urgently and what can be achieved with optimum care.

 
Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Lipodystrophy is a heterogeneous group of rare metabolic disorders characterised by the loss of adipose tissue and leptin deficiency. Typical symptoms include insulin resistance, diabetes and hypertriglyceridaemia, which if left untreated, can lead to complications including hepatic steatosis, pancreatitis, and early-onset atherosclerosis can develop.

The information in this activity is intended for healthcare professionals involved in the diagnosis and treatment of patients with lipodystrophy.

Part of this touchSYMPOSIUM HIGHLIGHTS was recorded live during the e-ECE 2020: the 22nd European Congress of Endocrinology in September 2020. The symposium was organised by Amryt Pharmaceuticals DAC.

Learning Objectives

After watching this activity participants should be better able to:

  • Recognise the main signs, symptoms and complications of lipodystrophy and its subtypes
  • Understand the main challenges to a diagnoses of lipodystrophy and how a definitive diagnosis is made
  • Describe the role of specialist centres in the diagnosis and management of lipodystrophy
  • Understand the burden of lipodystrophy and why it is important to initiate treatment quickly to prevent complications
  • Demonstrate knowledge of how to effectively manage lipodystrophy and the associated metabolic complications
Adverse Events
Adverse Events

Adverse reactions should be reported to Amryt Pharmaceuticals DAC by email medinfo@amrytpharma.com or by telephoning the free phone number: 00800 4447 4447. Adverse reactions can also be reported via the Yellow Card Scheme at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.

References
References
  1. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab. 2016;101:4500–11.
  2. Chehab FF. Obesity and lipodystrophy-where do the circles intersect? Endocrinology. 2008;149:92–34.
  3. Chiquette E, Oral EA, Garg A, et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10: 375–83.
  4. Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19:107–16.
  5. Lima JG, Nobrega LH, de Lima NN, et al. Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophy. Diabetol Metab Syndr. 2016; 8:23.
  6. Krawiec P, Mełges B, Pac-Kożuchowska E, et al. Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl. BMC Pediatr. 2016;16:38.
  7. Patni N, Li X, Adams-Huet B, et al. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants. J Clin Endocrinol Metab. 2019;104:1099–108.
  8. Akinci B, Oral EA, Neidert A, et al. Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. J Clin Endocrinol Metab. 2019;104:5120–35.
  9. Akinci B, Unlu SM, Celik A, et al. Renal complications of lipodystrophy: A closer look at the natural history of kidney disease. Clin Endocrinol (Oxf). 2018;89:65–75.
  10. Akinci B, Onay H, Demir T, et al. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey. J Clin Endocrinol Metab. 2016;101:2759–67.
  11. Amryt Pharmaceuticals Myalepta Summary of Product Characteristics; Weblink: https://www.ema.europa.eu/en/documents/product-information/myalepta-epar-product-information_en.pdf(accessed October 2020).
  12. Brown RJ, Valencia A, Startzell M, et al. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. J Clin Invest. 2018;128:3504–16.
  13. Brown RJ, Oral EA, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine. 2018;60:479–89.
  14. Oral EA, Gorden P, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine. 2019;64:500–11.
  15. Baykal AP, Parks EJ, Shamburek R, et al. Leptin decreases de novo lipogenesis in patients with lipodystrophy. JCI Insight. 2020;5(14).
  16. Ali. O, Cook. K, Lee. D, et al. Discrete choice and SF-36 estimates of patient quality of life and benefits of leptin replacement therapy (LRT) in generalized and partial lipodystrophy (GL, PL) (P589). European Congress of Endocrinology. Lyon, France; 2019.
  17. Ali OA, Cook K, Gupta D, et al. Effect of Leptin Replacement Therapy (LRT) on Survival and Disease Progression in Generalized and Partial Lipodystrophy (GL, PL). Diabetes. 2018;67(Supplement 1):106-LB.
Downloads

View and download resources from this activity to support your learning.

Feedback Close
Feedback

Please provide feedback for this touchSYMPOSIUM HIGHLIGHTS on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72